Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.

Clinical trial NCT03929107 · UNKNOWN

Trial details

NCT number: NCT03929107
Sponsor: Wenbin Qian
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

B Cell Lymphoma

Start date: 2019-03-28
Primary completion: 2022-01-31
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.